Nektar Therapeutics (LON:0UNL)
0.836
+0.005 (0.63%)
Jan 31, 2025, 6:33 PM BST
Nektar Therapeutics Employees
Nektar Therapeutics had 137 employees as of December 31, 2023. The number of employees decreased by 79 or -36.57% compared to the previous year.
Employees
137
Change (1Y)
-79
Growth (1Y)
-36.57%
Revenue / Employee
507.22K GBP
Profits / Employee
-916.56K GBP
Market Cap
136.02M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
AstraZeneca | 89,900 |
GSK plc | 70,212 |
Haleon | 25,408 |
Smith & Nephew | 18,452 |
Hikma Pharmaceuticals | 9,100 |
ConvaTec Group | 10,136 |
HUTCHMED (China) | 1,988 |
Genus | 3,500 |
Nektar Therapeutics News
- 6 weeks ago - Nektar Therapeutics Announces Completion of Target Enrollment in REZOLVE-AD Phase 2b Clinical Trial of Rezpegaldesleukin in Patients with Moderate-to-Severe Atopic Dermatitis - PRNewsWire
- 2 months ago - Nektar Therapeutics (NKTR) Stock Plummets Amidst Biotech Sector Decline - GuruFocus
- 2 months ago - Nektar Therapeutics Announces NKTR-255 Following CD19-directed CAR-T Therapy Enhanced Complete Response Rates in Patients with Relapsed or Refractory Large B-cell Lymphoma at the 66th Annual ASH Meeting - PRNewsWire
- 3 months ago - Nektar Therapeutics Presents First Preclinical Data from Novel CSF-1 Program, NKTR-422, at 2024 American College of Rheumatology (ACR) Convergence - PRNewsWire
- 3 months ago - Multiple Catalysts Ahead For Nektar Therapeutics - Seeking Alpha
- 3 months ago - Nektar Therapeutics (NKTR) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Nektar Therapeutics Reports Third Quarter 2024 Financial Results - PRNewsWire
- 3 months ago - Nektar and Collaborators Present Late-breaking Results from Phase 2 Study of NKTR-255 for the Treatment of Radiation Induced Lymphopenia in Locally Advanced Non-Small Cell Lung Cancer Patients at Society for Immunotherapy of Cancer (SITC) Annual Meeting - PRNewsWire